Many Rheumatologists Reluctant to Address Hypertension

30.10.20131575
Fewer than 1 in 3 rheumatologists report discussing hypertension with patients who have uncontrolled blood pressure, despite the fact that those with rheumatoid arthritis are at increased risk for cardiovascular disease compared with the general population and that hypertension is a modifiable risk factor.

Discovery Could Lead to Anti-Clotting Drugs With Less Risk of Bleeding

29.10.20131696
Researchers at the University of Illinois at Chicago have discovered a molecular switch that causes small, beneficial clots that stop bleeding to enlarge further during wound healing.

Inhibiting a Single Protein Could Improve Treatment of Atherosclerosis

28.10.20131493
Researchers of the Spanish research council (Consejo Superior de Investigaciones Cient?ficas, CSIC) and the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have discovered that inhibiting the protein Rcan1 in mice reduces the burden of atherosclerosis, one of the commonest cardiovascular diseases.

Catheter Ablation vs. Antiarrhythmic Drug Treatment of Persistent Atrial Fibrillation: A Multicenter, Randomized, Controlled Trial (SARA Study)

25.10.20131534
Is radiofrequency catheter ablation (RFCA) more effective than antiarrhythmic drug therapy (AADT) for preventing persistent atrial fibrillation (AF)?

6-Minute Walk Time Predicts TAVI Outcome

24.10.20131687
Among patients with chronic obstructive pulmonary disease (COPD) undergoing transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis, worse exercise capacity at baseline was associated with poorer outcomes, researchers found.

Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients

23.10.20131621
Among nontraditional cardiovascular risk factors, recent influenzalike infection is associated with fatal and nonfatal atherothrombotic events.

Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial

22.10.20131589
Рatients with Marfan syndrome have an increased risk of life-threatening aortic complications, mostly preceded by aortic dilatation. Treatment with losartan, an angiotensin-II receptor-1 blocker, may reduce aortic dilatation rate in Marfan patients.
Данный сайт и вся информация на нём предназначена для медицинских работников. Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.